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Purpose: Integrins play crucial roles in the pathogenesis of papillary thyroid carcinoma (PTC). The aim of this study was to 
investigate whether two single nucleotide polymorphisms (SNPs) (rs2141698, -1687A/G; rs11895564, Ala380Thr) of the in-
tegrin alpha 6 (ITGA6) gene are associated with the development and clinicopathologic characteristics of PTC such as the size 
(＜1 cm and ≥1 cm), number (unifocality and multifocality), location (one lobe and both lobes), extrathyroid invasion, and 
cervical lymph node metastasis. Methods: We enrolled 104 PTC patients and 318 control subjects. Genotypes of each SNP 
were determined by direct sequencing. SNPStats, SNPAnalyzer, and Helixtree programs were used to evaluate odds ratios 
(ORs), 95% confidence intervals (CIs), and P-values. Multiple logistic regression models were performed to analyze genetic 
data. Results: A missense SNP rs11895564 was associated with the development of PTC. The A allele frequency of rs11895564 
was higher in PTC patients than in controls (13.5% vs. 7.1%; P = 0.005; OR, 2.04; 95% CI, 1.24 to 3.37). In the clinicopathologic 
characteristics, the A allele frequency of rs11895564 showed difference in the size (19.6% in ＜1 cm vs. 6.9% in ≥1 cm; P = 
0.010; OR, 0.30; 95% CI, 0.12 to 0.75) and number (8.5% in unifocality vs. 20.8% in multifocality; P = 0.015; OR, 2.85; 95% CI, 
1.23 to 6.59) of PTC. Conclusion: These results suggest that the A allele of rs11895564 (Ala380Thr) in ITGA6 may be a risk fac-
tor of PTC, and also contribute to the progression of PTC in the Korean population.
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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the predominant 
type of thyroid cancers and develops in the follicular cells 
of the thyroid. It is the most rapidly increasing cancer, 
probably because of the increased detection of small, 
low-risk PTC. The incidence of PTC rapidly increases in 
worldwide during the past 10 to 20 years. According to the 
data from the National Cancer Center in Korea (http:// 
www.cancer.go.kr), among adolescents and adults be-ITGA6 polymorphisms and PTC
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tween ages 15 years and 64 years, thyroid cancer is the first 
most common cancer, and PTCs are the most common of 
all thyroid cancers. Most PTC patients with thyroi-
dectomy following the treatments of thyroid hormone 
suppression and radioactive iodine ablation have a good 
prognosis. However, PTC recurs in some patients and is 
the major one of endocrine cancer deaths [1,2]. To date, the 
tailored target therapies for the patients who fail to re-
spond to the initial treatment paradigm and who have the 
progressive and refractory cancers are being investigated. 
Environmental factors such as radiation, hormones, diet, 
and smoking are risk factors of PTC, and genetic factor has 
also implicated as a risk factor for the development and 
progression of PTC [3-5].
The extracellular matrix (ECM) (i.e., thrombospondin 1 
[THBS1, also known as TSP1] and fibronectin 1 [FN1]) 
plays a crucial role in the maintenance of cell and morpho-
genesis of tissue. ECM interacts with the cell adhesion 
molecules (CAMs) including integrins, CD36, CD44, and 
the immunoglobulin superfamily. CAMs provide a force 
of physical link between ECM and the cytoskeleton [6-9]. 
The ECM-CAM interactions also affect in the tumor micro-
environments such as tumor cell adhesion, proliferation, 
migration, invasion, and metastasis [10-12]. Integrins are 
transmembrane proteins and compose of an alpha chain 
and a beta chain. Integrin, alpha 6 (ITGA6) is a member of 
ECM adhesion receptor, and interacts beta chains, making 
the heterodimeric complexes consisting of one alpha chain 
and one beta chain (α6β1 and α6β4) [9,13]. Both α6β1 and 
α6β4 may play critical roles in the progression of cancers 
and be involved in the initial formation of cancerous 
tumors. Abnormal expression of α6β4 in the suprabasal 
cell layers has been associated with an increased malig-
nancy of squamous cell carcinomas [10-12]. Integrins par-
ticipate in cellular signalings such as the mitogen-acti-
vated protein kinase (MAPK)/nuclear factor of kappa light 
polypeptide gene enhancer in B-cells (NFKB), phosphoi-
nositide-3-kinase (PI3) kinase/v-akt murine thymoma vi-
ral oncogene homolog (AKT), and mothers against decap-
entaplegic homolog (SMAD) signalings [14-16]. In partic-
ular, α6β1 directly bind THBS1 in thyroid cancer cells and 
this complex then activates the MAPK signaling. These ac-
tions may remodel the ECM microenvironments and elicit 
tumor cell invasion into the lymph node and other tissues 
from the basement membrane, causing the progression of 
thyroid cancer [17]. Although integrins may be involved 
in PTC susceptibility, the genetic determinants have not 
yet been fully defined. 
In this study, we explored the relationship between 
ITGA6 SNPs and PTC, and their clinicopathologic charac-
teristics in Korean population.
METHODS
We enrolled 104 PTC patients (29 males and 75 females) 
and 318 control subjects (105 males and 213 females). PTC 
patients were selected among participants who visit at the 
Departments of Surgery and Otolaryngology-Head and 
Neck Surgery. Subjects with nodular hyperplasia, ana-
plastic carcinoma, follicular carcinoma, double primary of 
PTC and follicular carcinoma, and follicular variant of 
PTC were excluded. PTC was confirmed by pathologic 
examinations. Controls were recruited from healthy par-
ticipants through a general health check-up program. 
Subjects with thyroid disease, cancers, and any severe dis-
eases were excluded. Informed consent was obtained from 
all subjects. This study was conducted in accordance with 
the guidelines of the Helsinki Declaration. Patients were 
divided into subgroups in accordance to the size (＜1 cm 
and ≥1 cm), number (unifocality and multifocality), loca-
tion (one lobe and both lobes), extrathyroidal invasion 
(present and absent), lymph node metastasis (present and 
absent), and angiolymphatic invasion (present and ab-
sent). 
For the selection of ITGA6 SNPs, we searched the pro-
moter and coding regions of the ITGA6 gene in the SNP 
database of the National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/SNP, BUILD 
132). The SNPs with unknown heterozygosity or hetero-
zygosity below 0.1 and unknown minor allele frequency 
(MAF) or MAF below 0.1 were excluded. Out of 14 pro-
moter SNPs, there were 3 unknown heterozygosity, 2 het-
erozygosity below 0.1, 1 unknown MAF, and 7 MAF below 
0.1. Among 12 missense SNPs, SNPs with unknown heter-
ozygosity or heterozygosity below 0.1 were 9 and SNPs Su Kang Kim, et al.
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Variable 　 PTC Control 
Total number (n)  　 104 318
Age (yr, mean ± SD)  53.2 ± 11.9 57.9 ± 12.1
Gender (male/female) 29/75 105/213
Size of cancer
 ＜1 cm 51
 ≥1 cm 51
Number of cancer 
 Unifocality 65
 Multifocality 36
Location of cancer 
 One lobe 65
 Both lobe 35
Extrathyroidal invasion 
 Absent 48
 Present 53
Cervical lymph node metastasis 
 Absent 65
 Present 32
Angiolymphatic invasion 
 Absent 93
 Present 　   6 　
PTC, papillary thyroid cancer; SD, standard deviation.
PTC patients with inappropriate and insufficient clinical data 
were excluded.
Table 1. Demographic and clinicopathologic characteristics of the 
study population 
with unknown MAF were 2. Finally, one promoter SNP 
(rs2141698, -1687A/G) and one missense SNP (rs11895564, 
Ala380Thr) were selected. 
Genomic DNA was extracted from peripheral blood us-
ing DNA Isolation Kit for Cells and Tissues (Roche Diag-
nostics Co., Indianapolis, IN, USA) and genotyping of 
each SNP was determined using direct sequencing (Ma-
crogen Inc., Seoul, Korea). Polymerase chain reactions 
(PCRs) were conducted with the following primers: for 
rs2141698 (sense, 5’-GTTAACAGCTGGTGTGACATGG- 
3’; antisense, 5’-TTAGCCTTTTCCCTTCGTGTAA-3’; pro-
duct size, 324 bp) and for rs11895564 (sense, 5’- 
GGAGCCCCACAGTATTTTGATA-3’; antisense, 5’-TA-
GTTTCTCCCATGTTGGTCAGG-3’; product size, 348 bp). 
PCR comprised 40 cycles at 94
oC for 30 seconds, 58
oC for 30 
seconds, 72
oC for 30 seconds, and 1 cycle at 72
oC for 5 mi-
nutes for the final reaction. The PCR products were se-
quenced using the ABI PRISM 3730XL analyzer (Applied 
Biosystems, Foster City, CA, USA) and the sequencing da-
ta were analyzed by the SeqManII software (DNASTAR, 
Madison, WI, USA).
Hardy-Weinberg equilibrium (HWE) for each SNP in 
PTC patients and control subjects was estimated by the 
chi-square test. SNPStats (http://bioinfo.iconcologia.net/ 
index.php?module=Snpstats), SNPAnalyzer Pro (Istech 
Inc., Goyang, Korea), and Helixtree (Golden Helix, Boze-
man, MT, USA) were performed to obtain odds ratios 
(ORs), 95% confidence intervals (CIs), and P-values. 
Multiple logistic regression analysis and the Fisher’s exact 
test were conducted using the following models: codo-
minant1 (major allele homozygotes vs. heterozygotes), co-
dominant2 (major allele homozygotes vs. minor allele ho-
mozygotes), dominant (major allele homozygotes vs. het-
erozygotes ＋  minor allele homozygotes), recessive (major 
allele homozygotes ＋  heterozygotes vs. minor allele ho-
mozygotes), and log-additive (major allele homozygotes 
vs. heterozygotes vs. minor allele homozygotes). Age and 
gender as covariates were adjusted to obtain statistical 
significance. Haploview ver. 4.2 (Daly Lab, Cambridge, 
MA, USA) was used to determine the linkage disequi-
librium (LD) block and haplotypes between two SNPs. 
The data was also analyzed using SPSS ver. 18.0 (SPSS Inc., 
Chicago, IL, USA). The statistical significance level was set 
at P ＜  0.05.
RESULTS
Table 1 shows the demographic and clinicopathologic 
features of PTC patients and control subjects. The age of 
PTC patients and control subjects was 53.2 ± 11.9 (mean ± 
SD) and 57.9 ± 12.1 years, respectively. In the subgroups of 
PTC, the number of PTC patients with cancer size ≥1 cm 
and ＜1 cm was 51 (50%) and 51 (50%), respectively. The 
number of PTC patients with unifocality and multifocality 
was 65 (64.4%) and 36 (35.6%), respectively. Out of PTC pa-
tients, 65 (65%) and 35 (35%) subjects displayed one lobe 
and both lobe, respectively, and 48 (47.5%) and 53 (52.5%) 
subjects displayed no extrathyroidal invasion and present 
extrathyroidal invasion, respectively. The number of PTC 
patients with cervical lymph node metastasis and without 
cervical lymph node metastasis was 65 (67%) and 32 (33%), ITGA6 polymorphisms and PTC
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SNP
　
Type
Control PTC
Model OR (95% CI) P-value
Fisher’s exact 
P-value 　 n (%) n (%)
rs2141698  Genotype G/G 257 (80.8)   84 (80.8) Codominant1 1.11 (0.62-1.98) 0.806
-1687A/G A/G   57 (17.9)  20 (19.2) Codominant2 0.00 (0.00-NA) 0.999 0.576
A/A   4 (1.3)  0 (0.0) Dominant 1.05 (0.59-1.85) 0.880
Recessive 0.00 (0.00-NA) 0.180 0.576
Overdominant 1.12 (0.63-2.00) 0.690
Log-additive 0.98 (0.57-1.68) 0.940
Allele A   65 (10.2) 20 (9.6) 1
　　 G 571 (89.8) 188 (90.4) 　 1.07 (0.63-1.81) 0.801 　
rs11895564  Genotype G/G 274 (86.2)  78 (75.0) Codominant1 2.01 (1.13-3.57) 0.018
a)
Ala380Thr A/G   43 (13.5)  24 (23.1) Codominant2  5.88 (0.52-67.14) 0.113 0.129
A/A   1 (0.3)  2 (1.9) Dominant 2.11 (1.20-3.71) 0.011
a)
Recessive  5.23 (0.46-59.68) 0.170 0.152
Overdominant 1.97 (1.11-3.50) 0.024
a)
Log-additive 2.07 (1.23-3.51) 0.007
a)
Allele G 591 (92.9) 180 (86.5) 1
A 45 (7.1)  28 (13.5) 2.04 (1.24-3.37) 0.005
a)
ITGA6, integrin, alpha 6; SNP, singe nucleotide polymorphism; PTC, papillary thyroid cancer; OR, odds ratio; CI, confidence interval; NA, 
not applicable.
The P-values was calculated from logistic regression analysis adjusting sex and age. 
a)P-value means significance association.
Table 2. Genotype and allele distributions of ITGA6 SNPs in PTC patients and control subjects
SNP
　
Type
＜1 cm    ≥1 cm 
Model OR (95% CI) P-value
Fisher’s exact
P-value 　 n (%) n (%)
rs2141698 Genotype G/G 39 (76.5) 43 (84.3) 1
-1687A/G A/G 12 (23.5)  8 (15.7) 0.61 (0.22-1.63) 0.321
A/A 0 (0.0) 0 (0.0)
Allele A 12 (11.8) 8 (7.8) 1
　 G 90 (88.2) 94 (92.2) 　 1.57 (0.61-4.01) 0.349 　
rs11895564 Genotype G/G 33 (64.7) 44 (86.3) Codominant1 0.34 (0.12-0.93) 0.028
a)
Ala380Thr A/G 16 (31.4)  7 (13.7) Codominant2 0.00 (0.00-NA) 0.193
A/A 2 (3.9) 0 (0.0) Dominant 0.31 (0.11-0.83) 0.016
a)
Recessive 0.00 (0.00-NA) 0.495
Overdominant 0.36 (0.13-0.98) 0.040
a)
Log-additive 0.31 (0.12-0.81) 0.010
a)
Allele G 82 (80.4) 95 (93.1) 1
A 20 (19.6) 7 (6.9) 0.30 (0.12-0.75) 0.010
a)
ITGA6, integrin, alpha 6; SNP, singe nucleotide polymorphism; PTC, papillary thyroid cancer; OR, odds ratio; CI, confidence interval; NA, 
not applicable.
The P-values was calculated from logistic regression analysis adjusting sex and age. 
a)P-value means significance association.
Table 3. Genotype and allele distributions of ITGA6 SNPs according to the size of PTC 
respectively, and that with angiolymphatic invasion and 
without angiolymphatic invasion was 93 (93.9%) and 6 
(6.1%), respectively. The total numbers of PTC patients 
among subgroups were different, because subjects with 
inappropriate and insufficient clinical data were excluded 
(Table 1). 
The genotype and allele distributions of the two exam-
ined SNPs are presented in Tables 2-5. Two SNPs 
(rs2141698, -1687A/G; rs11895564, Ala380Thr) of the 
ITGA6 gene were in HWE in the PTC and control groups, Su Kang Kim, et al.
312 thesurgery.or.kr
SNP
　
Type
Unifocality Multifocality
Model OR (95% CI) P-value
Fisher’s exact 
P-value 　 n (%) n (%)
rs2141698 Genotype G/G   51 (78.5) 30 (83.3) 1
-1687A/G A/G   14 (21.5)  6 (16.7) 0.73 (0.25-2.10) 0.557
A/A     0 (0.0)  0 (0.0)
Allele A   14 (10.8)  6 (8.3) 1
G 116 (89.2) 66 (91.7) 　 1.33 (0.49-3.62) 0.580
rs11895564  Genotype G/G   54 (83.1) 23 (63.9) Codominant1 2.35 (0.89-6.20) 0.084
Ala380Thr A/G   11 (16.9) 11 (30.6) Codominant2 NA (0.00-NA) 0.097
A/A     0 (0.0)  2 (5.6) Dominant 2.77 (1.08-7.11)   0.034
a)
Recessive NA (0.00-NA) 0.125
Overdominant 2.15 (0.82-5.63) 0.120
Log-additive 2.86 (1.20-6.81)   0.015
a)
Allele G 119 (91.5) 57 (79.2) 1
A   11 (8.5) 15 (20.8) 2.85 (1.23-6.59)   0.015
a)
ITGA6, integrin, alpha 6; SNP, singe nucleotide polymorphism; PTC, papillary thyroid cancer; OR, odds ratio; CI, confidence interval; NA, 
not applicable.
The P-values wascalculated from logistic regression analysis adjusting sex and age. 
a)P-value means significance association.
Table 4. Genotype and allele distributions of ITGA6 SNPs according to the number of PTC
respectively (P ＞  0.05, data not shown). In Table 2, the gen-
otype distribution of a missense SNP (rs11895564, 
Ala380Thr) was associated with the development of PTC 
(P = 0.018; OR, 2.01; 95% CI, 1.13 to 3.57 in codominant1 
model; P = 0.011; OR, 2.11; 95% CI, 1.20 to 3.71 in dominant 
model; P = 0.024; OR, 1.97; 95% CI, 1.11 to 3.50 in over-
dominant model; P = 0.007; OR, 2.07; 95% CI, 1.23 to 3.51 in 
log-additive model). The A allele distribution of rs-
11895564 was higher in the PTC group than in the control 
group (13.5% vs. 7.1%; P = 0.005; OR, 2.04; 95% CI, 1.24 to 
3.37). The promoter SNP rs2141698 was not associated 
with the development of PTC in Korean population (Table 
2). These results indicate that rs11895564 of the ITGA6 
gene may be associated with the development of PTC, but 
rs2141698 not, and the A allele of rs11895564 might be a 
risk factor of PTC. All PTC patients were divided into sub-
groups according to the clinicopathologic characteristics. 
As shown in Table 3, the rs11895564 SNP was associated 
with the size of cancer (P = 0.028; OR, 0.34; 95% CI, 0.12 to 
0.93 in codominant1 model; P = 0.016; OR, 0.31; 95% CI, 
0.11 to 0.83 in dominant model; P = 0.040; OR, 0.36; 95% CI, 
0.13 to 0.98 in overdominant model; P = 0.010; OR, 0.31; 
95% CI, 0.12 to 0.81 in log-additive model). The A allele 
distribution of rs11895564 was lower in the size ≥1 cm 
group than in the size ＜1 cm group (6.9% vs. 19.6%; P = 
0.010; OR, 0.30; 95% CI, 0.12 to 0.75). The results suggest 
that ITGA6 rs11895564 may contribute to the size of PTC. 
In Table 4, the rs11895564 SNP had significant differences 
between PTC patients with unifocality and PTC patients 
multifocality (P = 0.034; OR, 2.77; 95% CI, 1.08 to 7.11 in 
dominant model; P = 0.015; OR, 2.86; 95% CI, 1.20 to 6.81 in 
log-additive model). The A allele distribution of rs-
11895564 in the multifocality group (20.8%) was about 
2.4-fold higher, compared to the unifocality group (8.5%). 
These data suggest that ITGA6 rs11895564 may be in-
volved in the multifocality of PTC. In addition, rs11895564 
was associated with the lymph node metastasis of PTC in 
only overdominant model (P = 0.029; OR, 0.27; 95% CI, 0.07 
to 0.99) (Table 5). The rs2141698 and rs11895564 were not 
contributed to the location and extrathyroidal invasion of 
PTC, respectively (data not shown). We did not evaluate 
on the angiolymphatic invasion of PTC, because the num-
ber of patients with angiolymphatic invasion was little (n 
= 6). Haploview ver. 4.2 was used to estimate the LD block 
between rs2141698 and rs11895564. The LD block in the 
control group was not made (D' = 0.192). Therefore, the 
analysis of haplotype was not performed.ITGA6 polymorphisms and PTC
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SNP
　
Type
Metastasis (－) M e t a s t a s i s  ( ＋)
Model OR (95% CI) P-value
Fisher’ exact
P-value 　 n (%)  n (%)
rs2141698 Genotype G/G   51 (78.5) 27 (84.4) 1
-1687A/G A/G   14 (21.5)  5 (15.6) 0.68 (0.22-2.07) 0.492
A/A   0 (0.0) 0 (0.0)
Allele A   14 (10.8) 5 (7.8) 1
　 G 116 (89.2) 59 (92.2) 　 1.42 (0.49-4.14) 0.516
rs11895564  Genotype G/G   46 (70.8) 28 (87.5) Codominant1 0.27 (0.07-1.00) 0.053
Ala380Thr A/G   18 (27.7) 3 (9.4) Codominant2  1.39 (0.08-23.57) 0.729 1.000 
A/A   1 (1.5) 1 (3.1) Dominant 0.33 (0.10-1.10) 0.052
Recessive  1.78 (0.11-29.95) 0.690 1.000 
Overdominant 0.27 (0.07-0.99)   0.029
a)
Log-additive 0.46 (0.16-1.29) 0.120
Allele G  110 (84.6) 59 (92.2) 1
A   20 (15.4) 5 (7.8) 2.15 (0.77-6.01) 0.146
ITGA6, integrin, alpha 6; SNP, singe nucleotide polymorphism; PTC, papillary thyroid cancer; OR, odds ratio; CI, confidence interval.
The P-values wascalculated from logistic regression analysis adjusting sex and age. 
a)P-value means significance association.
Table 5. Genotype and allele distributions of ITGA6 SNPs according to the cervical lymph node metastasis of PTC 
DISCUSSION
This study is first on the genetic relationships between 
ITGA6 SNPs and PTC in the Korean population. We ana-
lyzed the promoter SNP (rs2141698, -1687A/G) and mis-
sense SNP (rs11895564, Ala380Thr) in PTC patients and 
control subjects. We also investigated the association be-
tween two SNPs and the clinicopathologic characteristics 
of PTC. Our results revealed that a missense SNP 
(rs11895564) was associated with the development of PTC 
(P = 0.018 in codominant1, P = 0.011 in dominant, P = 0.024 
in overdominant, and P = 0.007 in log-additive models; P = 
0.005 in allele distributions). In recent, several researchers 
have reported the relationship between PTC and candi-
date genes including vascular endothelial growth factor A 
(VEGFA) [18], protein tyrosine phosphatase, receptor type, 
J (PTPRJ) [19], interleukin 6 (interferon, beta 2) (IL6) [20], 
IL10 [21], and collagen type XI α1 (COLIIAI)  [22]. To our 
knowledge, there is no study that investigated for the as-
sociation between ITGA6 and PTC. Only two studies were 
reported on the association between ITGA6 and cancers. 
Johnatty et al. [23] reported that an intron SNP (iSNP) 
rs13027811 of ITGA6 was related to ovarian cancer. The 
study by Cheng et al. [24] showed that the rs12621278 
iSNP of ITGA6 was strongly associated with the pro-
gression of prostate cancer. Like above mentioned two lit-
eratures, our results showed that a missense rs11895564 
SNP was associated with PTC. It is well-known that poor 
prognostic factors of PTC are thought to be large size, mul-
tifocality, multicentricity, extrathyroidal invasion, lymph 
node metastasis, age (＞50 years), male, and high histo-
logic grade [25-28]. When the maximum diameter of PTC 
is lesser 1 cm, papillary thyroid microcarcinoma (PTMC) 
is defined by the World Health Organization. PTMC gen-
erally appears good prognosis and therefore tend to have 
a less aggressive treatment, compared to conventional 
PTC. In contrast, some researchers have shown that the 
clinical feature of PTMC is similar pattern to PTC and they 
propose PTMC should be managed like the treatment of 
PTC [29,30]. In this study, the associations between a mis-
sense SNP (rs11895564) and the clinicopathologic charac-
teristics of PTC were found. The rs11895564 SNP was asso-
ciated with the size of cancer (＜1 cm vs. ≥1 cm) (P = 0.028 
in codominant1, P = 0.016 in dominant, P = 0.040 in over-
dominant, and P = 0.010 in log-additive models; P = 0.010 
in allele distributions), the number of cancer (unifocality 
vs. multifocality) (P = 0.034 in dominant and P = 0.015 in 
log-additive models; P = 0.015 in allele distributions), and Su Kang Kim, et al.
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the lymph node metastasis (present vs. absent) (P = 0.029 in 
overdominant model). The A/G genotype and A allele dis-
tributions of rs11895564 in PTC with the cancer size ≥1 cm 
(A/G genotype, 13.7%; A allele, 6.9%) were about 2.3 and 
2.8-fold lower than those in PTC with the cancer size ＜1 
cm (A/G genotype, 31.4%; A allele, 19.6%), respectively. 
The rs11895564 SNP was also associated with the number 
of PTC. The A/G genotype and G allele distributions of 
rs11895564 in PTC with multifocality (A/G genotype, 
30.6%; A allele, 20.8%) were about 1.8 and 2.4-fold higher, 
compared to PTC with unifocality (A/G genotype, 16.9%; 
A allele, 8.5%), respectively. The rs11895564 SNP was con-
tributed to the lymph node metastasis of PTC. The A/G 
genotype and A allele distributions of rs11895564 in PTC 
with the lymph node metastasis (A/G genotype, 9.4%; A 
allele, 7.8%) were about 2.9 and 2.0-fold lower than those 
in PTC without the lymph node metastasis (A/G genotype, 
27.7%; A allele, 15.4%), respectively. These results indicate 
that the A allele of rs11895564 has a protective effect to the 
size and lymph node metastasis of PTC, whereas that is a 
risk factor to the multifocality of PTC. Although we cannot 
exactly explain the difference effect of the A allele on each 
clinicopathologic characteristic of PTC, the change of ami-
no acid in the rs11895564 SNP may independently related 
to each clinical phenotype of PTC. In recent studies, poly-
morphisms of certain genes, such as v-raf murine sarcoma 
viral oncogene homolog B1 (BRAF), cyclin-dependent kin-
ase inhibitor 1B (CDKN1B), cholinergic receptor, nicotinic, 
alpha 3 (CHRNA3), and tumor necrosis factor (TNF-α) 
were associated with progression of cancers [31-35]. Chen 
et al. [34] reported that variant allele of rs1051730 in 
CHRNA3 gene was associated with larger tumor size at di-
agnosis of squamous cell carcinoma. They suggested that 
lung tumorigenesis may be driven not only by somatic 
mutations caused by tobacco carcinogens but also certain 
polymorphisms that may bring about physiological 
change. In present study, our results suggest one possi-
bility that the SNP of ITGA6 may be a risk factor of PTC, 
and also contribute to the progression of PTC.
Our study has several limitations. Firstly, sample size is 
small. Secondly, controls did not examine thyroid ultra-
sonography for the detection of potential thyroid cancers. 
Thirdly, the follow-up study was not performed. Another 
limitation is that the multi-variate analysis and other risk 
factors including age, and gender were not conducted. For 
the exact correlation between IGTA6 and PTC, additional 
studies with larger sample size and based on the multi- 
variate analysis could be needed.
In conclusion, our data suggest that a missense SNP 
(rs11895564, Ala380Thr) of the ITGA6 gene may be asso-
ciated with the development of PTC and could be a useful 
marker for the cliniopathologic characteristics such as the 
size, number, and lymph node metastasis of PTC in 
Korean population. 
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